2,120
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature

, , & ORCID Icon
Pages 168-170 | Received 01 Feb 2020, Accepted 27 Feb 2020, Published online: 21 May 2020

References

  • Morales A, Eidinger D, Bruce A. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–182.
  • Sylvester RJ, van der MEIJDEN AP, Witjes JA, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86–91.
  • Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J clin oncol. 2009;27(34):5680.
  • To U, Kim J, Chia D. Disseminated BCG: complications of intravesical bladder cancer treatment. Case Rep Med. 2014;2014:1–3.
  • Naudžiūnas A, Juškaitė R, Žiaugrytė I, et al. Tuberculosis complications after BCG treatment for urinary bladder cancer. Medicina (B Aires). 2012;48(11):82.
  • Ziegler J, Ho J, Gibson IW, et al. Disseminated Mycobacterium bovis infection post‐kidney transplant following remote intravesical BCG therapy for bladder cancer. Transplant Infect Dis. 2018;20(5):e12931.
  • Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clinl Infect Dis. 2000;31(Supplement_3):S91–S93.
  • Zhao W, Schorey JS, Bong‐Mastek M, et al. Role of a bacillus calmette‐guérin fibronectin attachment protein in BCG‐induced antitumor activity. Int J Cancer. 2000;86(1):83–88.
  • Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate-and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69–76.
  • Decaestecker K, Oosterlinck W. Managing the adverse events of intravesical bacillus Calmette–Guérin therapy. Res Rep Urol. 2015;7:157.
  • Hogarth M, Thomas S, Seifert M, et al. Reiter’s syndrome following intravesical BCG immunotherapy Postgrad. Med J. 2000 December;1:76.
  • Lukacs S, Tschobotko B, Szabo N, et al. Systemic BCG-osis as a rare side effect of intravesical BCG treatment for superficial bladder cancer. Case Rep Urol. 2013;2013:1–3.
  • Viana L. Oliveira e Castro, PdTd, Almeida, RDS, and Silva, RSPd, Sepse fatal após instilação intravesical de BCG: relato de caso. Rev Bras Ter Intensiva. 2011;23(1):104–107.
  • Bowyer L, Hall R, Reading J, et al. The persistence of bacille Calmette‐Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol. 1995;75(2):188–192.
  • Figueiredo C, Póvoas D, Alves C, et al. Septic shock after intravesical BCG instillation—A case report. Adv Infect Dis. 2013;3(4):243–247.
  • Liaw F, Tan YY, Hendry D. Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma. Clin Case Rep. 2017;5(10):1569.